Since β2m is a non-covalent binder to MHC1 molecules, upregulation of β2m could increase the level MHC1 complexes to interact with LILRB1 and therefore help cancer cells evade the innate immune system during tumor progression (94). Here, LILRB1 is linked to cancer.